A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes

Inclusion Criteria:

- Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months

- Insulin naïve subjects (Allowed are: previous short term insulin treatment up to 14
days; treatment during hospitalisation or during gestational diabetes is allowed for
periods longer than 14 days)

- Current treatment: metformin monotherapy or metformin in any combination with an
insulin secretagogue (sulfonylurea or glinide), dipeptidyl peptidase IV (DPP-IV)
inhibitor, alfa-glucosidase-inhibitors (acarbose) with unchanged dosing for at least
3 months prior to randomisation (Visit 2) with the minimum doses stated: metformin:
alone or in combination (including fixed combination) 1500 mg daily, or maximum
tolerated dose (at least 1000 mg daily), insulin secretagogue (sulfonylurea or
glinide): minimum half of the daily maximal dose according to local labelling, DPP-IV
inhibitor: minimum 100 mg daily or according to local labelling,
alfa-glucosidase-inhibitors (acarbose): minimum half of the daily maximal dose or
maximum tolerated dose

- HbA1c (glycosylated haemoglobin) 7.0-10.0% (both inclusive) by central laboratory
analysis

- BMI (Body Mass Index) below or equal to 40.0 kg/m^2

Exclusion Criteria:

- Treatment with TZDs (thiazoledinedione), or GLP-1 (glucagon-like peptide 1) receptor
agonists within the last 3 months prior to Visit 1 (screening)

- Anticipated change in concomitant medication known to interfere significantly with
glucose metabolism, such as systemic corticosteroids, beta-blockers, MAO (monoamine
oxidase) inhibitors

- Cardiovascular disease within the last 6 months prior to Visit 1 (screening) defined
as stroke; decompensated heart failure NYHA (New York Heart Association) class III or
IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass
graft or angioplasty

- Any clinically significant disease or disorder, except for conditions associated with
type 2 diabetes mellitus, which in the Investigator's opinion could interfere with
the results of the trial

- Previous participation in this trial. Participation is defined as randomised.
Re-screening of screening failures is allowed only once within the limits of the
recruitment period

- Known or suspected hypersensitivity to trial product(s) or related products